Acute Central Serous Chorioretinopathy Clinical Trial
Official title:
Randomized Controlled Clinical Trial to Evaluate the Effects of 577nm Micropulse Laser vs Traditional Laser Therapy on Acute Central Serous Chorioretinopathy
Central serous chorioretinopathy (CSC) is a relatively frequent eye disease in younger
patients. It is characterized by serous detachment of the neurosensory retina with or without
serous detachment of the retinal pigment epithelium (RPE), which can cause vision drop, image
distortion, loss of color and contrast vision. Although nonfoveal focal leakage can be
treated with traditional laser photocoagulation, but it has the side effects of causing RPE
atrophy, scotoma, or secondary CNV. Photodynamic therapy (PDT) is another effective treatment
but it's more than most families can afford to pay because of the high cost, what's more, it
is accompanied with side-effects, such as choroidal ischemia, retinal pigmental epithelium
(RPE) atrophy and RPE rip.
To date there is no international consensus on the optimal treatment of CSC Many
retrospective studies suggest that micropulse laser (MPL) therapy may also be effective
without obvious complications in this disease.
The purpose of this study is to evaluate the effect of micropulse laser (MPL) on acute
central serous chorioretinopathy compared with the traditional laser coagulation.
The study is a prospective randomized controlled trial about 577nm micropulse laser versus traditional laser coagulation therapy on acute central serous chorioretinopathy. The primary outcome measures is the proportion of eyes with complete absorption of subretinal fluid 3 months after treatment. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02587767 -
577nm Micropulse Laser vs Half-dose Photodynamic Therapy on Acute Central Serous Chorioretinopathy
|
N/A |